Magnetic Nanoparticles: New Players in Antimicrobial Peptide Therapeutics.

López-Abarrategui, Carlos; Figueroa-Espí, V.; Reyes-Acosta, Osvaldo; Reguera, E.; Otero‐González, Anselmo J.

doi:10.2174/1389203711209070682

Cited by 16 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, factors like the possible instability of Cm‐p5, biodistribution, and fungicidal activity need to be improved to augment their therapeutic potential. In this sense, the development of nanoparticles for entrapment and delivery of AMPs could represent an alternative (65, 66).…”

Section: Discussionmentioning

confidence: 99%

Cm-p5: an antifungal hydrophilic peptide derived from the coastal mollusk Cenchritis muricatus (Gastropoda: Littorinidae)

López-Abarrategui

McBeth²,

Mandal³

et al. 2015

The FASEB Journal

View full text Add to dashboard Cite

Antimicrobial peptides form part of the first line of defense against pathogens for many organisms. Current treatments for fungal infections are limited by drug toxicity and pathogen resistance. Cm-p5 (SRSE-LIVHQRLF), a peptide derived from the marine mollusk Cenchritis muricatus peptide Cm-p1, has a significantly increased fungistatic activity against pathogenic Candida albicans (minimal inhibitory concentration, 10 mg/ml; EC 50 , 1.146 mg/ml) while exhibiting low toxic effects against a cultured mammalian cell line. Cm-p5 as characterized by circular dichroism and nuclear magnetic resonance revealed an a-helical structure in membranemimetic conditions and a tendency to random coil folding in aqueous solutions. Additional studies modeling Cm-p5 binding to a phosphatidylserine bilayer in silico and isothermal titration calorimetry using lipid monophases demonstrated that Cm-p5 has a high affinity for the phospholipids of fungal membranes (phosphatidylserine and phosphatidylethanolamine), only moderate interactions with a mammalian membrane phospholipid, low interaction with ergosterol, and no interaction with chitin. Adhesion of Cm-p5 to living C. albicans cells was confirmed by fluorescence microscopy with FITC-labeled peptide. In a systemic candidiasis model in mice, intraperitoneal administration of Cm-p5 was unable to control the fungal kidney burden, although its low amphiphaticity could be modified to generate new derivatives with improved fungicidal activity and

show abstract

Section: Discussionmentioning

confidence: 99%

Cm-p5: an antifungal hydrophilic peptide derived from the coastal mollusk Cenchritis muricatus (Gastropoda: Littorinidae)

López-Abarrategui

McBeth²,

Mandal³

et al. 2015

The FASEB Journal

View full text Add to dashboard Cite

show abstract

“…Future clinical studies of these hydrogels and other delivery technologies will determine their safety and efficiency. Additional drug delivery strategies include carbon nanotubes and magnetic nanoparticles (López-Abarrategui et al, 2013;Chaudhari et al, 2016).…”

Section: Delivery and Formulationsmentioning

confidence: 99%

Antifungal Peptides as Therapeutic Agents

Ullivarri

Arbulu

García-Gutiérrez

et al. 2020

Front. Cell. Infect. Microbiol.

160

132

View full text Add to dashboard Cite

Fungi have been used since ancient times in food and beverage-making processes and, more recently, have been harnessed for the production of antibiotics and in processes of relevance to the bioeconomy. Moreover, they are starting to gain attention as a key component of the human microbiome. However, fungi are also responsible for human infections. The incidence of community-acquired and nosocomial fungal infections has increased considerably in recent decades. Antibiotic resistance development, the increasing number of immunodeficiency-and/or immunosuppression-related diseases and limited therapeutic options available are triggering the search for novel alternatives. These new antifungals should be less toxic for the host, with targeted or broader antimicrobial spectra (for diseases of known and unknown etiology, respectively) and modes of actions that limit the potential for the emergence of resistance among pathogenic fungi. Given these criteria, antimicrobial peptides with antifungal properties, i.e., antifungal peptides (AFPs), have emerged as powerful candidates due to their efficacy and high selectivity. In this review, we provide an overview of the bioactivity and classification of AFPs (natural and synthetic) as well as their mode of action and advantages over current antifungal drugs. Additionally, natural, heterologous and synthetic production of AFPs with a view to greater levels of exploitation is discussed. Finally, we evaluate the current and potential applications of these peptides, along with the future challenges relating to antifungal treatments.

show abstract

“…should be attributed to the altered pharmacokinetic behaviors of PEGylated D-Lip compared to free antagomir-10b, as more antagomir-10b loaded liposomes could be retained within tumors (as shown in Endeavors have been attempted for researchers to develop nano-sized carriers delivering anti-microbial peptides (AMPs) for infection therapy or oncotherapy [53][54][55]. However, not enough attention has been received for AMPs as to their capacity to deliver pharmaceuticals.…”

Section: In Vivo Delivery Of Antagomir-10b Loaded Liposomesmentioning

confidence: 99%